Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome by Prinsen, H. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/108175
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
RESEARCH ARTICLE Open Access
Humoral and cellular immune responses after
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Abstract
Background: Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and disabling fatigue
that is medically unexplained and lasts longer than 6 months. Although it is possible to effectively treat CFS, the
nature of the underlying physiology remains unclear. Various studies have sought evidence for an underlying
disturbance in immunity. The aim of this study was to compare the humoral and cellular immune responses upon
influenza vaccination in CFS patients and healthy controls.
Results: Identical antibody titers were observed in CFS patients and healthy controls. Patients and controls
demonstrated similar seroprotection rates against all three virus-strains of the influenza vaccine, both pre- and
post-vaccination. Functional T cell reactivity was observed in both CFS patients and healthy controls. CFS patients
showed a non-significant, numerically lower cellular proliferation at baseline compared to controls. Vaccination
induced a significant increase in cellular proliferation in CFS patients, but not in healthy controls. Cytokine
production and the number of regulatory T cells were comparable in patients and controls.
Conclusions: The humoral and cellular immune responses upon influenza vaccination were comparable in CFS
patients and healthy controls. Putative aberrations in immune responses in CFS patients were not evident for
immunity towards influenza. Standard seasonal influenza vaccination is thus justified and, when indicated, should
be recommended for patients suffering from CFS.
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Background
Chronic fatigue syndrome (CFS) is a clinical condition
characterized by severe and disabling fatigue that is
medically unexplained and lasts longer than 6 months
[1]. The estimated worldwide prevalence of CFS is
0.4-1% [2]. The existing evidence suggests that cognitive
behavior therapy, specifically designed for CFS, is an
effective treatment option [3-10]. However, although it
is possible to effectively treat CFS, the nature of the
underlying pathophysiology remains unclear.
Hypotheses explaining the pathophysiological mech-
anism of CFS include morphological and metabolic
alterations in the brain, [11-17] diminished central ac-
tivation of muscles, [18] altered central nervous system
functioning, [2] a neuroendocrine disturbance, [2] or
cognitive impairment [2]. Furthermore, the presence of
an underlying immunological problem has been sug-
gested as an explanation for CFS [2]. Cytokine dysre-
gulation, decreased natural killer cell functioning, the
presence of autoantibodies, and a reduced response of
T cells to mitogens and other specific antigens have been
reported in CFS [2,19,20]. If immunity is disturbed in
CFS patients, they might have an altered response to vac-
cination. Vaccines, accompanying adjuvants, and silicone
breast implants could act in concert in the development
of CFS [2,19-21]. Therefore, the aim of this study was to
compare the humoral and cellular immune responses
upon vaccination, using seasonal influenza vaccination as
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a model of a vaccination, in CFS patients and healthy
controls.
Results
Baseline characteristics
Baseline characteristics of the participants are presented
in Table 1.
Humoral immune response
Vaccination induced a significant increase in hemagglutination-
inhibition (HI) antibody titers for influenza strain H3N2
and H1N1 in the CFS group as well as in the healthy
control group (Figure 1A and 1B). For influenza strain B,
vaccination induced no significant increase in HI anti-
body titers, neither in the CFS, nor in the healthy control
group (Figure 1A and 1B). No significant differences
in HI antibody titers between both groups were observed
prior to vaccination or at day 22. Compared to the
healthy controls, CFS patients demonstrated similar
seroprotection rates (both pre- and post-vaccination)
and seroresponse rates against all three virus-strains
(Table 2).
Cellular immune response
Prior to vaccination, T cells proliferated upon phyto-
hemagglutinin (PHA) and virus stimulation in both
CFS patients and healthy controls (respectively 14,883
±4,265counts and 22,997±3,902 counts), indicating
that these T cells are functional (Figure 1C and 1D).
Cellular proliferation showed no significant differences
between CFS patients and healthy controls at baseline
(Table 2). Of note, in absolute counts, CFS patients
showed at baseline a lower T cell proliferation upon
stimulation in comparison with controls. Interleukin-
10 (IL-10) production and the number of regulatory T
lymphocytes (Treg) were not significantly different be-
tween CFS patients and healthy controls at baseline
(Table 2).
Vaccination induced a significant increase in cellular
proliferation in CFS patients after stimulation with influ-
enza strain H3N2 and B, and a trend in the same direc-
tion for strain H1N1, whereas in healthy controls
vaccination induced no significant change in cellular pro-
liferation after stimulation with any of the three virus-
strains (Figure 1C and 1D and Table 2).
Post-vaccination, T cell proliferation showed no sig-
nificant differences between CFS patients and controls,
neither for the three different virus strains (Figure 1C
and 1D), nor for PHA (respectively 34,964±4433 counts
and 15,406±2719 counts). Of note, in absolute counts,
CFS patients showed post-vaccination more proliferating
T cells upon stimulation with all three virus-strains,
compared to controls. Interferon gamma (IFN-γ),
interleukin-4 (IL-4), and interleukin-5 (IL-5) produc-
tion post-vaccination were not significantly different
between CFS patients and healthy controls (Table 2).
Discussion
To the best of our knowledge, we are the first to explore
both the humoral and cellular immune responses after
influenza vaccination in CFS patients. The hypothesized
immunological aberrancy claimed to be operative in CFS
could not be confirmed by our data.
Both CFS patients and healthy controls showed a sig-
nificant increase in humoral immune responses from
pre- to post-vaccination for virus-strains H3N2 and
Table 1 Baseline characteristics
Chronic fatigue syndrome patients (n=20) Healthy controls (n=20) p-value
Gender
Male 7 (35) 7 (35) 1.000
Female 13 (65) 13 (65)
Age (years)
Mean 35.0±10.0 34.4±9.2 0.857
CIS-fatigue 48.15±5.48 15.80±3.62 <0.001
Hemoglobin (mmol/l) 8.6±0.6 8.4±0.7 0.235
Mean absolute leukocyte count (*109/l) 7.2±1.9 6.9±1.9 0.654
Mean neutrophil count (% of total) 60.2±8.7 59.9±8.7 0.928
Mean lymphocyte count (% of total) 29.8±7.6 29.2±7.1 0.797
Mean monocyte count (% of total) 5.7±1.5 5.2±1.4 0.332
Influenza vaccination prior to 2010
Yes 5 (25) 5 (25) 1.000
No 15 (75) 15 (75)
Data are presented as mean ± standard deviation or as absolute numbers with percentages in brackets.
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H1N1. Virus-strain B did not show such an increase
from day 1 to day 22, but for this virus-strain the HI titer
was already high prior to vaccination.
In a previous study, only the effect of influenza vaccin-
ation on the antibody response of CFS patients was
determined in 40 CFS patients and 21 matched healthy
volunteers [22]. In accordance with our study, influenza
vaccination provided protective antibody levels. Our
study gives additional information on cellular immune
responses in CFS patients.
We observed that, although not statistically significant,
the incorporation of tritium thymidine by proliferating
T cells at baseline was numerically lower in patients
suffering from CFS in comparison to healthy controls.
To investigate whether it is worthwhile to investigate
this trend in more detail, we studied immunological
mechanisms commonly known to suppress immunity.
First, the immunosuppressive cytokine IL-10, which is
able to inhibit T cell proliferation, was assessed [23].
However, production at baseline of IL-10 was similar
in patients and controls. Secondly, Treg are known to
negatively modulate T cell responses [24]. Nevertheless,
the percentage of Treg in CFS patients at baseline did not
differ from the controls. Another possible explanation
for the decreased number of proliferating T lymphocytes
in CFS patients is elevated numbers of co-inhibitory
molecules, like programmed death-1, [25,26] cytotoxic
T lymphocyte antigen-4, [25] or B and T lympho-
cyte attenuator [27]. Whether inhibitory mechanisms
play a role in CFS patients need to be explored in
more detail.
From pre- to post-vaccination, CFS patients showed
a significant increase in cellular proliferation in two
out of three virus-strains and a trend in the same dir-
ection for the third virus-strain, whereas healthy con-
trols did not show a significant change in proliferation
from day 1 to day 8. In absolute counts, CFS patients
showed post-vaccination more proliferating T cells for
all three virus-strains, compared to controls. This non-
significant elevation in cellular immune responses could
not be explained by an increase in the levels of cytokines
IFN-γ, IL-4, and IL-5, cytokines involved in the type 1
and type 2 helper T cell responses, suggesting a type 0
helper T cell response in CFS patients after vaccination.
Limitations of the study
Given the exploratory nature of this study, group sizes
were relatively small and not based on power calcula-
tions. Consequently, subtle differences between CFS
patients and healthy controls may have gone unnoticed.
However, the sample size of our study was sufficiently
high to show that CFS patients are able to mount a
Figure 1 Hemagglutination inhibition antibody responses before (day 1) and after (day 22) influenza vaccination, and cellular
proliferation before (day 1) and after (day 8) influenza vaccination. Both immune responses are presented for the three influenza strains of
the vaccine (H3N2, H1N1, and B), in chronic fatigue syndrome patients (A and C) and healthy controls (B and D). Antibody titers are presented as
mean ± standard error of the mean, the dotted line indicates the protective titer cut-off value. Proliferation counts are presented as absolute
numbers and mean (horizontal line) on a logarithmic scale.
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significant protective antibody response and a sufficient
cellular immune response upon a single shot of influ-
enza vaccine.
Conclusions
In conclusion, putative aberrations in immune responses
in CFS patients were not evident for immunity towards
influenza. We show that CFS patients are able to mount
a protective antibody response and a sufficient cellular
immune response upon a single shot of influenza vac-
cine, which is comparable with healthy controls. There-
fore, standard seasonal influenza vaccination is thus
justified and, when indicated, should be recommended
for patients suffering from CFS.
Methods
Participants
The study population consisted of a group of CFS
patients (n=20) and a group of healthy controls (n=20).
CFS patients fulfilled the Centre for Disease Control and
prevention criteria for CFS [1] and were referred for
cognitive behavior therapy to the Expert Centre for
Chronic Fatigue of the Radboud University Nijmegen
Medical Centre (RUN-MC, Nijmegen, the Netherlands).
CFS patients were asked to bring a gender- and age-
matched non-fatigued friend as a control. Fatigue sever-
ity was measured by the fatigue severity subscale of the
Checklist Individual Strength (CIS-fatigue) [28,29]. A
cutoff score of ≥35 points on this subscale indicates se-
vere fatigue and a score of <27 points signifies normal
fatigue feelings. All participants were between 18 and
60 years old. The local ethics committee of the RUN-MC
approved the study and all participants provided written
informed consent.
Vaccination and blood collection
Between September 2010 and January 2011, all parti-
cipants were intramuscularly vaccinated with a single
dose of the inactivated trivalent split influenza vac-
cine (VaxigripR, Sanofi Pasteur MSD, Hoofddorp, the
Netherlands), which contained inactivated, split virion
of the three influenza strains (A/H3N2/Perth/16/2009,
A/H1N1/California/7/2009, and B/Brisbane/60/2008).
Peripheral blood mononuclear cells (PBMC) were col-
lected at baseline (day 1) and 7 days after vaccination
(day 8), and serum was collected at baseline and 21 days
after vaccination (day 22) [30].
Humoral immune response
The humoral immune responses on influenza vaccin-
ation were measured in serum by the HI antibody test as
described previously [31]. The virus antibody responses
were measured at day 1 and day 22 for the three differ-
ent influenza strains of the vaccine (A/H3N2/Perth/16/
2009, A/H1N1/California/01/2010, and B/Florida/004/
2006). Seroprotection was defined as an antibody titer of
at least 1:40 [31,32]. Post-vaccination seroresponse was
defined as at least a four-fold increase in titers [32].
Cellular immune response
The cellular immune responses were measured by T
lymphocyte proliferation and cytokine secretion of
PBMC collected at day 1 and 8, and the presence of Treg
at day 1.
Table 2 Humoral and cellular immune responses
Chronic fatigue
syndrome patients
(n=20)
Healthy
controls
(n=20)
p-value
Seroprotection rate pre-vaccination (day 1)
H3N2 13 (65) 12 (60) 0.744
H1N1 4 (20) 5 (25) 0.705
B 16 (80) 17 (85) 0.677
H3N2, H1N1, and B 2 (10) 4 (20) 0.376
Seroprotection rate post-vaccination (day 22)
H3N2 18 (90) 20 (100) 0.147
H1N1 18 (90) 18 (90) 1.000
B 18 (90) 20 (100) 0.147
H3N2, H1N1, and B 15 (75) 18 (90) 0.212
Seroresponse rate post-vaccination (day 1 to 22)
H3N2 10 (50) 12 (60) 0.525
H1N1 13 (65) 12 (60) 0.744
B 2 (10) 3 (15) 0.633
H3N2, H1N1, and B 1 (5) 2 (10) 0.548
IL-10 production at baseline (day 1, pg/ml)
H3N2 4.5±10.9 2.5±5.0 0.457
H1N1 65.6±127.4 35.3±47.2 0.329
B 19.3±56.0 10.5±20.2 0.514
Treg at baseline (day 1, %)
Unstimulated 2.8±1.2 2.7±1.5 0.733
IFN-γ production post-vaccination (day 8, pg/ml)
H3N2 162.1±220.5 116.0±180.8 0.474
H1N1 578.3±828.8 382.5±446.1 0.360
B 316.4±520.7 418.1±528.9 0.544
IL-4 production post-vaccination (day 8, pg/ml)
H3N2 0.0±0.0 4.3±13.5 0.169
H1N1 0.0±0.0 7.7±20.2 0.105
B 2.9±8.8 0.0±0.0 0.163
IL-5 production post-vaccination (day 8, pg/ml)
H3N2 1.4±4.3 1.7±4.7 0.811
H1N1 1.2±3.4 1.5±4.5 0.788
B 0.8±3.4 3.4±6.4 0.114
Data are presented as absolute numbers with percentages in brackets or as
mean ± standard error of the mean.
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For analysis of lymphocyte proliferation and cytokine
secretion, 1.5x105 PBMC were added per well of a 96-
wells plate in culture medium (RPMI 1640 supplemented
with 4% human serum albumin). In the proliferation
assay, PBMC were incubated with 1μg/ml PHA and with
a 1:10 dilution of the separate virus-strains (A/H3N2/
Perth/25/11/2008, A/H1N1/California/01/2010, and B/
Florida/05/11/2008). After 48 hours of culture, super-
natant was harvested to analyze cytokine production.
The Th1/Th2 11plex kit (eBioscience, San Diego, CA)
was used according to the manufacturer’s protocol in
order to measure IL-10 at day 1 and IFN-γ, IL-4, and
IL-5 at day 8. After four days of culture, 1 μCi 3[H]-
thymidine (MP Biomedicals, Santa Ana, California, USA)
was added to each well for overnight incubation to
measure T lymphocyte proliferation.
Multi-color flow cytometric analysis was performed on
unstimulated PBMC collected at day 1 according to the
manufacturer’s protocol. Cells were stained for anti-
CD4/FITC (Beckman Coulter), anti-CD25/PE-Cy7 (BD
Biosciences, Breda, the Netherlands), anti-CD127/PE
(BD Bioscience), and anti-FOXP3/APC (clone PCH101,
eBioscience). Treg were defined as CD4+CD25++CD127-
FOXP3+ and were expressed as a percentage of CD4
+CD25++CD127- cells.
Statistics
Statistical analyses were performed using PASW for
WindowsW, version 18.0.2 (Armonk, New York, USA).
Independent samples t tests were performed to assess
differences in numerical variables at day 1, 8, and 22.
Paired t tests were used to assess changes in numerical
variables from pre- to post-vaccination. Chi-square tests
were performed to compare groups on categorical vari-
ables. Differences were considered statistically significant
at p<0.05.
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